ACOR News 34.62 Acorda Therapeutics (ACOR)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Acorda Therapeutics (ACOR) 34.62 $ACOR

Upgrade Alert for Acorda Therapeutics (ACOR)
Comtex SmarTrend(R) - Mon Apr 14, 7:11AM CDT
Acorda Therapeutics (NASDAQ:ACOR) was upgraded from Market Perform to Outperform at FBR Capital today. The stock closed yesterday at $35.19 on volume of 351,000 shares, below average daily volume of 464,000. Acorda Therapeutics Inc. is a biotechnology company that is developing therapies for spinal cord injury and related neurological conditions, including multiple sclerosis. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain.

Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting
Business Wire - Mon Apr 14, 6:30AM CDT
--- New TECFIDERA(R) (dimethyl fumarate) Data Underscore Efficacy, Consistent with Growing Global Experience with Greater than 65,000 Patients Treated Worldwide(1) -

19.4% Return Seen to Date on SmarTrend Acorda Therapeutics Call (ACOR)
Comtex SmarTrend(R) - Fri Apr 11, 11:10AM CDT
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 2 months, Acorda Therapeutics has returned 19.43% as of today's recent price of $37.00.

Acorda Therapeutics Shares Up 22.8% Since SmarTrend's Buy Recommendation (ACOR)
Comtex SmarTrend(R) - Fri Apr 04, 9:45AM CDT
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 2 months, Acorda Therapeutics has returned 22.76% as of today's recent price of $38.03.

23.1% Return Seen to Date on SmarTrend Acorda Therapeutics Call (ACOR)
Comtex SmarTrend(R) - Fri Mar 28, 9:18AM CDT
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 1 month, Acorda Therapeutics has returned 23.14% as of today's recent price of $38.15.

Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech
M2 - Thu Mar 27, 4:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rbvwd8/global) has announced the addition of the "Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech" report to their offering. Positive sentiments for the biotech sector have prevailed in the last two to three years, and the authors expect this trend to continue for the next year too. The optimism is based on the continuity in the flow of innovative products from the biotech pipeline, implementation of strategic decisions to improve cost efficiency, strengthen therapeutic leadership, and hedge against generic threats - which all lend stability to the business model. Focus and interest in Orphan diseases remains and Alexion kept everyone guessing on the possible acquisition. BMRN, Alexion are likely candidates to be acquired in this space. In the next five years the distinction between some mature biotech companies and large global pharma may become blurred especially if there is consolidation within the sector. AMGN was the first amongst the peers to declare a dividend and this has raised the bar/expectations from others too. First mAb Biosimilar (Hospira's infliximab - Inflectra) was approved in EU and the pipeline, competition intensifies despite no firm regulatory pathway being defined in the US. This report contains the detailed discussion of the key attributes of leading biotech companies' Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron and Vertex. Key Topics Covered: 1. Acorda Therapeutics - Pipeline of NDDS Drugs targeting Niche Indications 2. Alexion Pharma - Focus on Innovative Drugs for Orphan/ Ultra-rare Diseases with No Competition Visible! 3. Amgen - Late-Stage Pipeline Carries Potential to Counteract Expected Headwinds 4. Biogen Idec - Near-Term Growth Prospects Driven by Core Business New Product Launches 5. Celgene - Innovative Strategies for Long Term Gains 6. Regeneron - Label Expansion Sustains Eylea's Growth Momentum Late Stage Pipeline 7. Vertex Pharma - Focus Shift to Cystic Fibrosis and Niche Indications Companies Mentioned: - Acorada - Alexion - Amgen - Biogen Idec - Celgene - Gilead Sciences - Regeneron - Vertex Pharma For more information visit http://www.researchandmarkets.com/research/rbvwd8/global

Acorda Joins Participants from Around the World in Recognizing Purple Day(R) to Raise Epilepsy Awareness
Business Wire - Wed Mar 26, 7:05AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today joins people with epilepsy, advocacy organizations and healthcare professionals in recognizing Purple Day(R). On March 26th people in countries around the world are invited to wear purple and host events in support of epilepsy awareness. Purple Day(R) was founded in 2008 by nine-year-old Cassidy Megan of Nova Scotia, and launched internationally in 2009. The Epilepsy Association of Nova Scotia and the Anita Kaufmann Foundation in the United States are the global partners for the Purple Day campaign(R). One in 26 Americans will develop epilepsy during their lifetime.(1)

Acorda Therapeutics Has Returned 22.7% Since SmarTrend Recommendation (ACOR)
Comtex SmarTrend(R) - Thu Mar 13, 11:11AM CDT
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 4 weeks, Acorda Therapeutics has returned 22.69% as of today's recent price of $38.01.

Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Uptrend Call Working As Acorda Therapeutics Stock Rises 26.2% (ACOR)
Comtex SmarTrend(R) - Thu Mar 06, 9:52AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 3 weeks, Acorda Therapeutics has returned 26.17% as of today's recent price of $39.09.

Acorda Therapeutics (ACOR) Jumps: Stock Rises 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:18AM CST
Acorda Therapeutics, Inc. (ACOR) was a big mover last session, as the company saw its shares rise by roughly 8% on the day.

Acorda Therapeutics (ACOR) Marked As A Barbarian At The Gate
at The Street - Tue Mar 04, 11:41AM CST
Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Shares of ACOR Up 18.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 27, 9:23AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 2 weeks, Acorda Therapeutics has returned 18.30% as of today's recent price of $36.65.

Acorda Therapeutics to Present at the Cowen & Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer, and Mike Rogers, Acorda's Chief Financial Officer, will present at the Cowen & Company 34th Annual Health Care Conference on Monday, March 3 at 4:10 pm ET at the Marriott Copley Plaza Hotel in Boston.

BioLineRx appoints Dr Sandra Panem to board
M2 - Tue Feb 25, 5:59AM CST
Biopharmaceutical company BioLineRx (NASDAQ:BLRX)(TASE:BLRX), headquartered in Israel, revealed on Monday the addition of Dr Sandra Panem PhD to its board of directors.

BioLineRx Appoints Dr. Sandra Panem to Board of Directors
PR Newswire - Mon Feb 24, 6:00AM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the appointment of Sandra Panem, Ph.D., to its Board of Directors.

Acorda Up After Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 1:53PM CST
Acorda misses Q4 earnings estimates

Acorda Therapeutics to Present at Citi 2014 Global Healthcare and RBC Capital Markets Conferences in February
Business Wire - Tue Feb 18, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that it will present at the Citi 2013 Global Healthcare and RBC Capital Markets conferences in February.

Acorda Therapeutics (ACOR) Soars: Stock Adds 10% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 7:51AM CST
Acorda Therapeutics, Inc. was a big mover last session, as its shares rose over 10% on the day.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 111

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 406

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 7

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 70

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 50

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 97

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 63

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 5

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 67

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding DraftKings Options Activity and Market Trends

Updated Category News Views 194

DraftKings: Analyzing Recent Options Activity In the world of financial trading, few stories capture attention quite like a company's options activity, especially when it comes to a prominent name such as DraftKings (NASDAQ: DKNG). Recently, significant bullish moves by major investors have been noted, illustrating a dynamic shift within the trading environment. Insights...

Continue Reading
Integrating Bitcoin into Modern Investment Strategies

Updated Category News Views 259

Why Bitcoin Is Essential in Today's Investment Landscape For many investors, Bitcoin remains a puzzling investment vehicle. A recent survey revealed that a significant portion of the population lacks confidence in the safety and reliability of cryptocurrencies. However, when industry leaders like BlackRock make statements regarding Bitcoin, it’s wise to take heed....

Continue Reading
Strengthening Global Ties: ICAC's Role in Combating Corruption

Updated Category News Views 240

Strengthening Global Ties: ICAC's Role in Combating Corruption In a significant development, the ICAC Commissioner Mr. Woo Ying-ming represented the International Association of Anti-Corruption Authorities (IAACA) at the G20 Anti-Corruption Working Group meeting, marking the first occasion for the ICAC to participate in such a global dialogue. The meeting brought together...

Continue Reading
FlexTV's New Release: A Drama of Love and Intrigue

Updated Category News Views 447

FlexTV Unveils English Adaptation of a Short Drama Mega Matrix Inc. (NYSE American: MPU) is thrilled to announce the premiere of its much-anticipated short drama Drink Me, Keep Me, Cut Me, now available in English on their streaming platform, FlexTV. This series offers viewers a tantalizing glimpse into the intricate relationship dynamics intertwined with love and...

Continue Reading
Canada Eases Mortgage Switch Process for Borrowers

Updated Category News Views 87

Canada's Mortgage Game-Changer: Easing Lender Switching In a bold move that could shake up the housing market, Canada’s banking regulator has rolled out a directive set to streamline how homeowners switch lenders during mortgage renewals. Finally! This change aims to chop through the red tape that often kept borrowers shackled to less favorable terms. The Short-Term...

Continue Reading